Joel Tepper is an Oncology physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 414 publications with 26,495 citations (h-index 76); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Radiation Oncology profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
Sponsor: UNC Lineberger Comprehensive Cancer Center
- Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Sponsor: Radiation Therapy Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2000–2019 per NIH RePORTER. The latest:
- Nano Approaches to Modulate Host Cell Response for Cancer Therapy
Univ of North Carolina Chapel Hill
FY2019$2,191,356U54CA198999 - Nano Approaches to Modulate Host Cell Response for Cancer Therapy
Univ of North Carolina Chapel Hill
FY2018$2,261,936U54CA198999 - Nano Approaches to Modulate Host Cell Response for Cancer Therapy
Univ of North Carolina Chapel Hill
FY2017$2,636,624U54CA198999
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Radiation therapy‐associated toxicity: Etiology, management, and prevention
CA A Cancer Journal for Clinicians
2021 - Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
Nature Nanotechnology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Douglas Drossman, MD
University of North Carolina at Chapel Hill
Michael Knowles, MD
University of North Carolina at Chapel Hill
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”